A study of INT-747 (6-ethyl chenodeoxycholic acid [6-ECDCA]) in combination with ursodeoxycholic acid (UDCA [URSO]) in patients with primary biliary cirrhosis (PBC)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 04 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 May 2024 According to an Intercept Pharmaceuticals media release, 6-months results from this trial included in abstracts related to primary biliary cholangitis (PBC) and alcohol-related liver disease will be presented at EASL Congress 2024. The congress will be held from June 5-8 in Milan, Italy.
11 Jan 2024 Status changed from completed to discontinued. (Study stopped by sponsor due to administrative reasons)
13 Sep 2022 Results published in the Gastroenterology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com